Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease
Collaboration combines molecular biomarkers with AI-enabled digital assessments to support more precise characterization of neurodegenerative disease
Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, and Modality.AI, a leader in AI-enabled multimodal clinical assessments, today announced a collaboration to explore how molecular biomarkers and objective digital assessments can be combined to improve the characterization of central nervous system (CNS) disorders.
The collaboration brings together Amprion's expertise in detecting disease-specific misfolded proteins with Modality.AI's browser-based Tina platform, which uses structured audiovisual conversations to generate objective measures of speech, language, facial expression, cognition, and behavior to track disease progression. Together, the companies aim to better characterize and monitor patients, support clinical research, and generate richer datasets for neurodegenerative disease studies.
"Neurodegenerative diseases aren't defined by a single signal, and they shouldn't be assessed that way," said Russ Lebovitz, MD, PhD, CEO and Co-Founder of Amprion. "At Amprion, our work has always been rooted in revealing the underlying biology of disease. By bringing together molecular biomarkers and scalable digital assessments, we have an opportunity to connect what's happening biologically with how disease presents and progresses in patients. That more complete picture can support better research, more informed clinical decision-making, and ultimately better patient outcomes."
